Apotransferrin Metal Ion Complex for Selective Thermal Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current thermal cancer therapies using electromagnetic waves face limitations due to non-selective heat generation in both cancerous and normal tissues, leading to reduced efficacy and safety concerns, as metal nanoparticles accumulate in both types of tissues and are not degraded or released in vivo.
Innovation Solution
A sensitizing composition comprising metal ions noncovalently bound to apotransferrin or apotransferrin derivatives, which selectively targets cancer cells via the transferrin receptor, allowing for increased metal ion concentration in tumorous tissue and enhanced heat generation upon electromagnetic wave application, minimizing damage to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If metal nanoparticles are used for thermal cancer therapy, then heat generation capability is improved, but selectivity between cancerous and normal tissues deteriorates
Solution Approach 1:
The patent uses apotransferrin as an intermediary carrier to deliver metal ions selectively to cancer cells. The apotransferrin binds metal ions (Fe3+, Ga3+, In3+) and transports them through the bloodstream, where they are selectively taken up by cancer cells via transferrin receptors. This mediator approach enables selective accumulation of heat-generating metal ions in tumor tissue while minimizing presence in normal tissues, thus resolving the contradiction between heat generation capability and tissue selectivity.
Solution Approach 2:
The patent changes the chemical form of metal from nanoparticle suspension to ion-bound-protein complex. By converting metal nanoparticles to metal ions bound to apotransferrin, the system achieves different biological behavior: the protein-metal ion complex can be selectively recognized and internalized by cancer cells through transferrin receptor-mediated endocytosis, whereas metal nanoparticles lack this specific biological recognition mechanism. This parameter change from physical form to chemical-biological form enables selective delivery.
2Reliability
If electromagnetic waves are applied to generate heat in tumorous tissue, then thermal therapy effectiveness is improved, but damage to normal tissue increases
Solution Approach 1:
The patent achieves local quality by concentrating metal ions specifically in the tumor region through apotransferrin-mediated delivery. The metal ions accumulate in cancer cells at much higher concentrations than in normal tissues. When electromagnetic waves are applied, heat generation occurs predominantly in the tumor region where metal ions are concentrated, while normal tissues receive minimal heat exposure. This spatial differentiation of heat generation resolves the contradiction between therapy effectiveness and normal tissue protection.
Solution Approach 2:
The apotransferrin-metal ion complex acts as a mediator that enables selective localization of heat-generating agents in tumor tissue. The complex is taken up by cancer cells through specific receptor interactions, creating a localized concentration of heat-generating metal ions in the tumor region. This mediator approach ensures that electromagnetic wave energy is converted to heat primarily in the target tissue, minimizing collateral damage to surrounding normal structures.
3Area of stationary object
If metal ions are delivered systemically, then coverage of all tumor sites is improved, but accumulation in normal tissue increases
Solution Approach 1:
The patent employs apotransferrin as a selective intermediary that enables systemic delivery while maintaining tumor-specific accumulation. The apotransferrin-metal ion complex circulates systemically and is recognized by transferrin receptors that are overexpressed on cancer cells. This receptor-mediated uptake mechanism ensures that metal ions are selectively internalized by tumor cells throughout the body, while normal cells with lower receptor expression accumulate minimal metal ions. This resolves the contradiction between broad tumor coverage and selective accumulation.
Solution Approach 2:
The patent changes the biological recognition parameter of the metal delivery system. By binding metal ions to apotransferrin, the system gains the ability to be specifically recognized and internalized by cancer cells through transferrin receptor interactions. This parameter change from non-specific metal ion distribution to receptor-mediated selective uptake enables systemic delivery with tumor-preferential accumulation, resolving the contradiction between coverage area and normal tissue concentration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sensitizing composition effectively increases heat generation in cancer cells while minimizing normal tissue damage, thereby improving the therapeutic efficacy of thermal cancer therapy by selectively delivering metal ions to cancer cells, enhancing the treatment's effectiveness and safety.
Implementation Method 1
When electromagnetic waves pass through a polar material, electromagnetic waves stimulate the molecular motion of the polar material to thus generate heat. Water molecules, which constitute most of the human body, have dipole moments through asymmetrical bonding between oxygen and hydrogen atoms. Because of the dipole moments of water molecules, water molecules that are exposed to electromagnetic waves upon 'thermal cancer therapy using electromagnetic waves' repeatedly undergo molecular rotation a number of times proportional to a frequency of electromagnetic waves, whereby the molecules are pulled or pushed to each other or collide with each other, consequently generating heat in the tissue exposed to the electromagnetic waves.
Implementation Method 2
A sensitizing composition comprising metal ions noncovalently bound to apotransferrin or apotransferrin derivatives, which selectively targets cancer cells via the transferrin receptor, allowing for increased metal ion concentration in tumorous tissue
Data Source
AI summary
Disclosed are a sensitizing composition for thermal cancer therapy using electromagnetic waves and a method of treating cancer using the composition. The sensitizing composition includes a metal ion, a metal ion-bound material, metal ion-noncovalently bound apotransferrin (transferrin), or a metal ion-noncovalently bound apotransferrin derivative. The sensitizing composition enables selective delivery of the metal ion to tumorous tissue when administered in vivo, and thus the generation of heat in tumorous tissue in which the metal ion accumulates is increased upon thermal cancer therapy using electromagnetic waves, thereby maximizing efficacy of thermal cancer therapy using electromagnetic waves in treating cancer. Thermal therapy using the sensitizing composition effectively treats cancer without pain or side effects and is thus expected to be widely useful in anticancer treatment as monotherapy, and/or in combination with chemotherapy, radiation therapy, or a combination thereof, ultimately increases the potential to cure cancer.